1-20 of 325
obinutuzumab
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA

Free
Clinical Trials & Observations
Steven Le Gouill, Hervé Ghesquières, Lucie Oberic, Franck Morschhauser, Hervé Tilly, Vincent Ribrag, Thierry Lamy, Catherine Thieblemont, Hervé Maisonneuve, Rémy Gressin, Krimo Bouhabdallah, Corinne Haioun, Gandhi Damaj, Luc Fornecker, Réda Bouhabdallah, Pierre Feugier, David Sibon, Guillaume Cartron, Christophe Bonnet, Marc André, Loic Chartier, Philippe Ruminy, Françoise Kraeber-Bodéré, Caroline Bodet-Milin, Alina Berriolo-Riedinger, Josette Brière, Jean-Philippe Jais, Thierry Jo Molina, Emmanuel Itti, René-Olivier Casasnovas
Journal: Blood
Blood (2021) 137 (17): 2307–2320.
https://doi.org/10.1182/blood.2020008750
Published: 2021
Includes: Supplemental data
Journal Articles

A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial

Free
Clinical Trials & Observations Brief Report
Anne-Sophie Michallet, Rémi Letestu, Magali Le Garff-Tavernier, Carmen Aanei, Michel Ticchioni, Marie-Sarah Dilhuydy, Fabien Subtil, Valerie Rouille, Beatrice Mahe, Kamel Laribi, Bruno Villemagne, Gilles Salles, Olivier Tournilhac, Alain Delmer, Christelle Portois, Brigitte Pegourie, Veronique Leblond, Cecile Tomowiak, Sophie De Guibert, Frederique Orsini Piocelle, Anne Banos, Philippe Carassou, Guillaume Cartron, Luc-Matthieu Fornecker, Loic Ysebaert, Caroline Dartigeas, Malgorzata Truchan-Graczyk, Jean-Pierre Vilque, Thérèse Aurran, Florence Cymbalista, Stéphane Lepretre, Vincent Levy, Florence Nguyen-Khac, Pierre Feugier
Journal: Blood
Blood (2021) 137 (8): 1019–1023.
https://doi.org/10.1182/blood.2020008164
Published: 2021
Includes: Supplemental data
Journal Articles

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax

Free
Clinical Trials & Observations
Eugen Tausch, Christof Schneider, Sandra Robrecht, Can Zhang, Anna Dolnik, Johannes Bloehdorn, Jasmin Bahlo, Othman Al-Sawaf, Matthias Ritgen, Anna-Maria Fink, Barbara Eichhorst, Karl-Anton Kreuzer, Maneesh Tandon, Kathryn Humphrey, Yanwen Jiang, William Schary, Lars Bullinger, Daniel Mertens, Michele Porro Lurà, Michael Kneba, Hartmut Döhner, Kirsten Fischer, Michael Hallek, Stephan Stilgenbauer
Journal: Blood
Blood (2020) 135 (26): 2402–2412.
https://doi.org/10.1182/blood.2019004492
Published: 2020
Includes: Supplemental data
Journal Articles

Baseline SUVmax did not predict histological transformation in follicular lymphoma in the phase 3 GALLIUM study

Free
Clinical Trials & Observations Brief Report
Farheen Mir, Sally F. Barrington, Helen Brown, Tina Nielsen, Deniz Sahin, Michel Meignan, Judith Trotman
Journal: Blood
Blood (2020) 135 (15): 1214–1218.
https://doi.org/10.1182/blood.2019001091
Published: 2020
Includes: Supplemental data
Journal Articles

Venetoclax-obinutuzumab: harnessing complexity

Free
Pau Abrisqueta, Francesc Bosch
Journal: Blood
Blood (2020) 135 (11): 788–789.
https://doi.org/10.1182/blood.2019004463
Published: 2020
Journal Articles

Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials

Free
Clinical Trials & Observations
Jennifer A. Woyach
Journal: Blood
Blood (2019) 134 (21): 1796–1801.
https://doi.org/10.1182/blood.2019001321
Published: 2019
Journal Articles

Venetoclax and obinutuzumab for frontline treatment of chronic lymphocytic leukemia

Free
Deborah M. Stephens
Journal: Blood
Blood (2019) 134 (20): 1691–1696.
https://doi.org/10.1182/blood.2019001750
Published: 2019
Journal Articles

Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab in First-Line Chronic Lymphocytic Leukemia in the United States

Free
Matthew S. Davids, MD, Anuja Chatterjee, MSc, Arliene Ravelo, MPH, Sheila Shapouri, PharmD, MS, Beenish S Manzoor, PhD, Kavita Sail, PhD, Gijs Van de Wetering, PhD, Michael Hallek
Journal: Blood
Blood (2019) 134 (Supplement_1): 4741.
https://doi.org/10.1182/blood-2019-123706
Published: 2019
Journal Articles

A Prognostic Model Integrating PET-Derived Quantitative Parameters and Image Texture Analyses Using Radiomics in a Large Prospective Phase III Trial, GOYA

Free
Lale Kostakoglu, MD MPH, Paola Berchialla, PhD, Federico Dalmasso, PhD, Larry A Pierce, PhD, Umberto Vitolo, Maurizio Martelli, MD, Laurie H Sehn, MD, Marek Trněný, MD, Tina G Nielsen, MD PhD, Christopher R Bolen, PhD, Deniz Sahin, BSc, Calvin Lee, MD, Tarec Christoffer C. El-Galaly, MD, Federico Mattiello, PhD, Paul E Kinahan, PhD, Stephane Chauvie, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 883.
https://doi.org/10.1182/blood-2019-123450
Published: 2019
Journal Articles

Ibrutinib, Venetoclax Plus Obinutuzumab in Newly Diagnosed Mantle Cell Lymphoma Patients

Free
Steven Le Gouill, MD PhD, Franck Morschhauser, MD, Kamal Bouabdallah, MD, Guillaume Cartron, Olivier Casasnovas, MD, Thomas Gastinne, MD, Patrice Chevallier, MD, Cédric Rossi, MD PhD, Emmanuelle Tchernonog, MD, Rory McCulloch, FRCPath, MRCP, MBBS, Charles Herbaux, MD, David Chiron, PhD, Mary Callanan, PhD, Simon Rule
Journal: Blood
Blood (2019) 134 (Supplement_1): 1530.
https://doi.org/10.1182/blood-2019-125681
Published: 2019
Journal Articles

Dual CD20-Targeted Therapy With Concurrent CD20-TCB and Obinutuzumab Shows Highly Promising Clinical Activity and Manageable Safety in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results From a Phase Ib Trial

Free
Franck Morschhauser, MD, Carmelo Carlo-Stella, MD, Fritz Offner, MD, Gilles A. Salles, MD PhD, Martin Hutchings, MD PhD, Gloria Iacoboni, MD, Anna Sureda, MD PhD, Michael Crump, MD, Joaquin Martinez-Lopez, MD PhD, Denise Thomas, MSc, Peter N Morcos, PharmD, Cristiano Ferlini, MD, Abiraj Keelara, PhD, Ann-Marie E Bröske, PhD, Marina Bacac, PhD, Natalie Dimier, PhD, Tom Moore, MBChB, Martin Weisser, MD, Michael Dickinson, MBBS,FRACP,FRCPA
Journal: Blood
Blood (2019) 134 (Supplement_1): 1584.
https://doi.org/10.1182/blood-2019-123949
Published: 2019
Journal Articles

Transcriptomic and Metabolomic Profiling Identifies Calcium-Dependent Signaling Mechanisms As a Novel and Exploitable Target to Overcome Anti-CD20 Resistance in Non-Hodgkin Lymphoma (NHL)

Free
Ravi Dashnamoorthy, PhD, Saheli Sarkar, PhD, Afshin Beheshti, PhD, Maisarah Mokhtar, B.S, Tali Konry, PhD, Michael Levin, PhD, Andrew M. Evens, DO, MSc
Journal: Blood
Blood (2019) 134 (Supplement_1): 1511.
https://doi.org/10.1182/blood-2019-126539
Published: 2019
Journal Articles

Complete Response Status According to RECIL 2017 Criteria Shows High Concordance with Lugano 2014 Criteria and Is Highly Prognostic for Outcome in Previously Untreated Patients with CD20-Positive Diffuse Large B-Cell Lymphoma (DLBCL)

Free
Lale Kostakoglu, MD MPH, Maurizio Martelli, MD, Laurie H Sehn, MD, Marek Trněný, MD, Umberto Vitolo, Andrea Knapp, PhD, Federico Mattiello, PhD, Tina G Nielsen, MD PhD, Deniz Sahin, BSc, Gila Sellam, PhD, Carol Ward, MSc, Anas Younes, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 489.
https://doi.org/10.1182/blood-2019-123626
Published: 2019
Journal Articles

Recapitulation of Prognostic Mutational Subtyping Utilizing F1H in GOYA and CAVALLI and the Potential to Highlight Benefit of Targeted Therapy in De Novo DLBCL

Free
Eugene C Kim, PhD, Jinzhen Fan, PhD, Christopher R Bolen, PhD, Alexandra Bazeos, MD PhD FRCPath, Yanwen Jiang, PhD, Sandhya Balasubramanian, MS, Rama Balakrishnan, PhD, Andrea Knapp, PhD, Kathryn Humphrey, BSc, Tina G Nielsen, MD PhD, Jeffrey M. Venstrom, MD PhD, Genevive Hernandez, PhD, Joseph N Paulson, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2788.
https://doi.org/10.1182/blood-2019-124687
Published: 2019
Journal Articles

Debulking Eliminates Need for Hospitalization Prior to Initiating Frontline Venetoclax Therapy in Previously Untreated CLL Patients: A Phase 3b Study

Free
Jeff P. Sharman, MD, David Andorsky, MD, Jason M. Melear, MD, Sudhir Manda, MD, Bertrand M. Anz, III, MD, Kathryn S. Kolibaba, MD, Habte A Yimer, MD, John M Burke, MD, Suzanne R. Fanning, DO, Jay Courtright, MD, Miguel Islas-Ohlmayer, MD, Suman Kambhampati, MD, Abdullah Al Masud, PhD, Todd Zimmerman, Jacqueline Nielsen, PhD, Tamas Vizkelety, Dingfeng Jiang, Ian W. Flinn, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3042.
https://doi.org/10.1182/blood-2019-127408
Published: 2019
Journal Articles

Sequential Treatment with Bendamustine, Obinutuzumab (GA101) and Ibrutinib in Chronic Lymphocytic Leukemia (CLL): Final Results of the CLL2-BIG Trial of the German CLL Study Group (GCLLSG)

Free
Julia Von Tresckow, Paula Cramer, Nisha De Silva, MBBS, MRCP, FRCPath, Jasmin Bahlo, PhD, Sandra Robrecht, PhD, Petra Langerbeins, MD, Anna- Maria Fink, MD, Othman Al-Sawaf, MD, Moritz Fürstenau, MD, Thomas Illmer, MD, Holger Klaproth, Eugen Tausch, Matthias Ritgen, Kirsten Fischer, MD, Clemens-Martin Wendtner, Karl-Anton Kreuzer, MD, Stephan Stilgenbauer, MD, Sebastian Böttcher, MD, Barbara F. Eichhorst, MD, Michael Hallek, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3046.
https://doi.org/10.1182/blood-2019-125895
Published: 2019
Journal Articles

A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (ONO/GS-4059) and Idelalisib with and without Obinutuzumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Free
Nadine Kutsch, MD, Christian Pallasch, Thomas Decker, Holger Hebart, Kai Uwe Chow, Ullrich Graeven, Jens Kisro, Alexander Kroeber, Eugen Tausch, Clemens-Martin Wendtner, Michael J. Eckart, Stephan Stilgenbauer, Xi Huang, Juliane M. Jürgensmeier, Pankaj Bhargava, Michael Hallek, Barbara F. Eichhorst, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3047.
https://doi.org/10.1182/blood-2019-131025
Published: 2019
Journal Articles

BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression

Free
Paul J. Hampel, MD, Timothy G. Call, MD, Sara J. Achenbach, Kari G Rabe, Wei Ding, MD PhD, Eli Muchtar, MD, Saad S. Kenderian, MD, Yucai Wang, MD PhD, Amber Koehler, PA-C, MS, Amie Fonder, PA-C, MS, Jose F. Leis, MD PhD, Susan M. Schwager, Daniel L. Van Dyke, PhD, Esteban Braggio, PhD, Susan L. Slager, PhD, Neil E. Kay, MD, Sameer A. Parikh, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3050.
https://doi.org/10.1182/blood-2019-125411
Published: 2019
Journal Articles

Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia

Free
Milos D. Miljkovic, MDMSc, Kevin C Conlon, MD, Jennifer Hsu, RN, Clare Sun, MD, Adrian Wiestner, MD PhD, Thomas A. Waldmann, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3052.
https://doi.org/10.1182/blood-2019-130807
Published: 2019
Journal Articles

CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Can be Safely Combined with the Anti-PD-L1 Antibody Atezolizumab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Free
Martin Hutchings, MD PhD, Giuseppe Gritti, MD PhD, Anna Sureda, MD PhD, Maria Jose Terol, Martin JS Dyer, DPhil, Gloria Iacoboni, MD, William Townsend, MRCP,MDFRCPath, Marina Bacac, PhD, Ann-Marie E Bröske, PhD, Natalie Dimier, PhD, Cristiano Ferlini, MD, Abiraj Keelara, PhD, Angelika Lahr, PhD, Katharina Lechner, MD, Tom Moore, MBChB, Peter N Morcos, PharmD, Anesh Panchal, MSc, Martin Weisser, MD, Ciel De Vriendt
Journal: Blood
Blood (2019) 134 (Supplement_1): 2871.
https://doi.org/10.1182/blood-2019-123978
Published: 2019